↓ Skip to main content

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Overview of attention for article published in Journal of Hematology & Oncology, January 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

blogs
1 blog

Citations

dimensions_citation
55 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Published in
Journal of Hematology & Oncology, January 2018
DOI 10.1186/s13045-017-0550-8
Pubmed ID
Authors

Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 19%
Student > Master 5 12%
Student > Bachelor 3 7%
Student > Ph. D. Student 3 7%
Other 2 5%
Other 7 16%
Unknown 15 35%
Readers by discipline Count As %
Medicine and Dentistry 11 26%
Biochemistry, Genetics and Molecular Biology 7 16%
Psychology 3 7%
Nursing and Health Professions 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Other 2 5%
Unknown 16 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2019.
All research outputs
#5,842,572
of 23,138,859 outputs
Outputs from Journal of Hematology & Oncology
#402
of 1,202 outputs
Outputs of similar age
#115,423
of 442,402 outputs
Outputs of similar age from Journal of Hematology & Oncology
#6
of 18 outputs
Altmetric has tracked 23,138,859 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,202 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,402 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.